Department of Pathology Microbiology and Immunology

From left, J.Court Reese, Stephanie Moore-Lotridge, PhD, Breanne Gibson, PhD, and Jonathan Schoenecker, MD, PhD, are discovering ways to prevent adverse outcomes in orthopaedic surgery.
January 19, 2022

Study identifies molecular trigger of severe injury-induced inflammatory response

Vanderbilt researchers have discovered that early inappropriate activation of the enzyme plasmin caused by severe injury is a trigger of systemic inflammatory response syndrome and resulting organ failure.

By Leigh MacMillan
January 17, 2022

H. pylori, lipid loss and stomach cancer

H. pylori infection — a strong risk factor for stomach cancer — changes the composition of stomach lipids, which could offer new biomarkers for detecting premalignant changes, Vanderbilt researchers discovered.

By Leigh MacMillan
January 13, 2022

Salmonella overcomes host resistance

The invading pathogen Salmonella, a common cause of food poisoning, can change its metabolism to overcome host resistance to its colonization.

By Leigh MacMillan
January 13, 2022

Study seeks to refine head and neck cancer treatment options

By Bill Snyder
December 2, 2021

Long-acting antibody combo developed at VUMC reduces COVID-19 risk and symptoms

By Bill Snyder
November 18, 2021

Seven from VUMC among most highly cited researchers

Seven Vanderbilt faculty members have made this year’s list of scientists whose papers have been cited most frequently by other researchers.

By Bill Snyder
November 11, 2021

CRISPR screen identifies new anti-inflammatory drug target

A novel CRISPR screen developed by Vanderbilt researchers identified a promising new target for anti-inflammatory therapeutics.
By Leigh MacMillan
October 28, 2021

VUMC researchers a step closer to broad ebolavirus protection

By Bill Snyder
October 13, 2021

Diagnostic Laboratory Services set for relocation, expansion

Vanderbilt's Diagnostic Laboratory Services are undergoing a major relocation and expansion project.
By Kathy Whitney
October 5, 2021

AstraZeneca seeks emergency approval for COVID-19 antibodies isolated at VUMC

Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.
By Bill Snyder
September 30, 2021

Molecular imaging of C. diff infection

C. difficile — the leading cause of hospital-associated intestinal infections — induces a rapid influx of bile acids into the gut, which could provide a novel target for blocking infection.
By Leigh MacMillan
September 22, 2021

“Ultra-potent” antibody against COVID-19 variants isolated at VUMC

A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.
By Bill Snyder
September 10, 2021

Caught in a web: study reveals that immune cells cooperate to trap and kill bacteria

Vanderbilt researchers have identified a new antibacterial mechanism that could inspire novel strategies for combating staph and other extracellular bacterial pathogens.
By Leigh MacMillan
1 … 7 8 9 10 11 … 32